The Secret Gem Of EPZ5676

A recent study has demonstrated that immunologically matched iPS cells http://www.selleck.cn/products/Staurosporine.html are more immunogenic than matched ES cells and cells derived from iPS cells trigger T-cell-dependent immune response in syngeneic recipients [21]. On the other hand, NSCs are known to display immunosuppressive properties and have been used to ameliorate experimental autoimmune encephalomyelitis [22�C25]. It is still unclear whether iPS-NSCs also display such properties and, if so, whether the immunosuppressive activity of NSCs is strong enough to abolish effects of NSC-mediated cancer gene therapy. To gain some preliminary insight into the issues, we repeated the above therapeutic experiment in immunocompetent BALB/c mice bearing syngeneic 4T1 tumors. Figure 5A, 5B shows that the median survival time of the NSCtk/GCV group was 39 days, the longest among all groups tested (p http://www.selleckchem.com/products/ly2109761.html Table S3). A small but statistically significant decrease in survival time was observed in the NSC/GCV group when compared with the PBS/GCV group in the immunocompetent mice (Fig. 5B; Supporting Information Table S3), indicating possible immunomodulatory effects of iPS-NSCs that promote tumor growth in a xenogeneic setting. Nevertheless, systemic injection of HSVtk-expressing iPS-NSCs coupled with GCV treatment offsetted the tumor growth-promoting effects and led to prolonged survival of tumor-bearing animals (Fig. 5A, http://www.selleckchem.com/products/epz-5676.html 5B, 5C; Supporting Information Table S3). Poor prognosis in malignant tumors is partially attributed to the ability of these tumors to infiltrate in the human body and the ineffectiveness of conventional therapies, such as surgery, radiotherapy, and chemotherapy, to eliminate disseminated tumors. Clearly, there is an urgent need to develop novel treatments to overcome the limitations of current cancer therapies. NSCs are able to home in on not just brain tumors but also solid tumors of a non-neural origin [1, 2]. Especially, the tumor tropism of NSCs has been used for targeted delivery of anticancer genes to both major tumor mass and distant tumor outgrowths in animal tumor models [1, 2, 5, 16, 26-36]. A phase I clinical trial of gene therapy for recurrent glioblastoma multiforme using a human NSC cell line to deliver a suicide gene is currently ongoing at the City of Hope Medical Center in Duarte, California. In animal models, the most commonly targeted types of tumors by NSC-based approaches are those in the central nervous system (CNS), including both neural originated tumors and brain metastases of non-neural tumors [1, 2, 5, 16, 26-36]. Aboody et al. have reported on the successful elimination of disseminated neuroblastoma tumors outside the CNS by i.v. injection of NSCs expressing an enzyme that activates the anticancer prodrug camptothecin-11 (CPT-11) [30, 37].